The purpose of this study is to assess medical events during follow-up of adult patients having hypophosphatasia and consulting rheumatologists.
Hypophosphatasia (HPP) is a rare inherited disease caused by mutations of the ALPL gene. In adult HPP, patients may suffer from fractures, pseudofractures, fracture healing complications, osteoarthritis, chondrocalcinosis, dental diseases, muscle pain and disability, but also headache, muscle weakness, ocular disease, and other symptoms. In some cases the diagnosis is severely delayed. Moreover a number of patients having such symptoms and a low level of serum alkaline phosphatase, without gene mutation can be followed by rheumatologists with difficulties in management of bone fragility and pain. The aim of this register is to describe prospectively the medical events in adult patients having hypophosphatasia, whether or not there is a proven genetic abnormality.
Study Type
OBSERVATIONAL
Enrollment
130
Collection data from diagnostic Data collected following to medical exam as part of care
CHU de Bordeaux- Hôpital Pellegrin Place Amélia Raba Léon - 12è étage - Rhumatologie -
Bordeaux, France, France
NOT_YET_RECRUITINGCHU Lille
Lille, France
RECRUITINGHospices Civils de Lyon
Characterise the circumstances of diagnosis, and deduce ways to reduce the diagnostic delay of hypophosphatasia in adults.
Time since first symptom due to hypophosphatasia
Time frame: At inclusion
Characterise "non bony" forms: chondrocalcinosis, multiple tendon calcifications, inflammatory pseudo-rheumatism, odonto-HPP
Proportion of each of the "non-bone" forms in the diagnosed population.
Time frame: At inclusion
Characterise the forms for which the genetic analysis is negative
Proportion of patients with clinical hypophasphatasia, without genetic evidence.
Time frame: At inclusion
Recognise situations of associated osteoporosis.
Proportion of patients with femoral and/or spinal densitometric osteoporosis.
Time frame: At 72 months
Characterise the practical follow-up of asfotase alpha treatment started in adults
Maintenance of enzyme replacement therapy.
Time frame: At 72 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Lyon, France
CHU Nice
Nice, France
RECRUITINGLariboisière Hospital
Paris, France
RECRUITINGCochin Hospital
Paris, France
RECRUITINGCHU Poitiers
Poitiers, France
RECRUITINGCHU Rennes
Rennes, France
RECRUITINGCHU Saint-Etienne
Saint-Priest-en-Jarez, France
RECRUITINGLes hôpitaux universitaires de Strasbourg
Strasbourg, France
RECRUITING...and 1 more locations